109 related articles for article (PubMed ID: 7904970)
1. [The erbB gene family: significance for tumor development, prognosis and new therapeutic modalities].
Beckmann MW; Niederacher D; Schnürch HG; Bender HG
Geburtshilfe Frauenheilkd; 1993 Nov; 53(11):742-53. PubMed ID: 7904970
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
[TBL] [Abstract][Full Text] [Related]
3. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
4. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
6. Altered gene expression in drug-resistant human breast cancer cells.
Wosikowski K; Schuurhuis D; Kops GJ; Saceda M; Bates SE
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2405-14. PubMed ID: 9815641
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study.
Shintani S; Funayama T; Yoshihama Y; Alcalde RE; Ootsuki K; Terakado N; Matsumura T
Anticancer Res; 1995; 15(6B):2623-6. PubMed ID: 8669836
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
9. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene.
Singleton TP; Strickler JG
Pathol Annu; 1992; 27 Pt 1():165-90. PubMed ID: 1346551
[TBL] [Abstract][Full Text] [Related]
11. [Proto-oncogene C-erbB-2 and human cancer].
Toyoshima K
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):309-14. PubMed ID: 1968737
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
13. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
14. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
[TBL] [Abstract][Full Text] [Related]
15. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
17. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi M; Romano A; Curia MC; Muraro R; Fedi P; Aaronson SA; Di Fiore PP; Kraus MH
Oncogene; 1995 May; 10(9):1813-21. PubMed ID: 7538656
[TBL] [Abstract][Full Text] [Related]
18. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.
Hudelist G; Singer CF; Manavi M; Pischinger K; Kubista E; Czerwenka K
Breast Cancer Res Treat; 2003 Aug; 80(3):353-61. PubMed ID: 14503808
[TBL] [Abstract][Full Text] [Related]
20. Oncogene abnormalities in astrocytomas: EGF-R gene alone appears to be more frequently amplified and rearranged compared with other protooncogenes.
Burgart LJ; Robinson RA; Haddad SF; Moore SA
Mod Pathol; 1991 Mar; 4(2):183-6. PubMed ID: 1675468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]